2021.02.05
I-Mab today announced multiple clinical advancements for its proprietary and highly differentiated CD73 antibody uliledlimab in advanced solid tumors.
2021.02.04
I-Mab today announced that the first patient has been dosed in a phase 2 clinical trial of TJ107, a novel long-acting recombinant human interleukin-7, in patients with glioblastoma multiforme (GBM) in China.
2021.01.25
I-Mab and MorphoSys today announced that the first patient has been dosed in a phase 1 dose escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of TJ210/MOR210 monotherapy in patients with relapsed or refractory advanced solid tumors in the United States.
2020.12.24
I-Mab announced its participation in upcoming conferences in January.
2020.12.14
I-Mab today announced that Company’s American Depositary Shares have been selected for inclusion in the NASDAQ Biotechnology Index, based on the results of the annual reconstitution of the index announced by Nasdaq on December 11, 2020.
2020.12.04
I-Mab today announced the advancement of clinical development of the highly differentiated anti-CD47 monoclonal antibody lemzoparlimab in the US and China, achieving milestones as planned.
2020.12.01
I-Mab today filed a registration statement on Form F-1 with the SEC by using a “shelf” registration process with respect to 25,123,751 ordinary shares of the Company beneficially owned by certain shareholders, which are parties to the privately negotiated subscription agreements with the Company dat...
2020.12.01
I-Mab today announced the strengthening of its Scientific Advisory Board with the appointment of leading international experts Dr. Chen Dong and Dr. Jun Ma.
2020.11.13
I-Mab will hold a call with investors on Friday, November 13 at 8:20 a.m. ET to provide deep dive analysis of preliminary clinical efficacy results of its U.S. phase 1 clinical trial evaluating lemzoparlimab for the treatment of relapsed or refractory solid tumors.
2020.11.11
Oral presentation highlights the unique epitope, pharmacological profile and anti-tumor properties of TJ210/MOR210.